Description
Tagrix (Osimertinib) 80mg Online
Tagrix (Osimertinib) is prescribed to treat metastatic non-small cell lung cancer in patients with T790M mutation in the epidermal growth factor receptor (EGFR) gene, who developed the progressive disease during and after EGFR tyrosine kinase inhibitor therapy. The medication can be prescribed only after the mutation has been confirmed by the laboratory tests.
Tagrix is an epidermal growth factor receptor (EGFR) kinase inhibitor. The medication irreversibly binds with the mutant forms of the EGFR genes (such as T790M, L858R, and a deletion in the 19th exon), which determine the resistance to other chemical substances. According to the research, Tagrix (Osimertinib Mesylate) proved highly active towards EGFR mutations of the non-small cell lung cancer and to a less degree towards wild type EGFR gene.
Dosage and administration usual recommended dose of Tagrix (Osimertinib Mesylate) is 80mg taken once a day. The tablets are taken orally with or without food. The treatment must be stopped if cancer deteriorates or intolerable adverse events occur. For patients experiencing difficulties swallowing the medication can be dissolved in 50ml of still water and administered through a nasogastric tube. If you miss a dose, the treatment should be continued according to the prescribed schedule. Do not take the missed dose.
After ingesting the medication, the following two metabolites are found in the blood of patients – AZ7550 and AZ5104, both of them possessing similar therapeutic effects. The range of activity of AZ7550 turned out to be identical to Osimertinib Mesylate, while AZ5104 showed higher efficiency against T790M mutation, deletion in the 19th exon, and wild type EGFR.
